source
- Endpoints launches nominations for its 2026 Women in Biopharma projectEndpoints announced that nominations are now open for its eighth annual Women in Biopharma initiative, which highlights contributions of women in the industry. The program, scheduled for 2026, see…
- Roche commits $700 million to co-develop Nurix's BTK-degrading drug bexobrutidegRoche announced a partnership with Nurix Therapeutics to co-develop a protein-degrading therapy called bexobrutideg, which targets the BTK enzyme. Under the agreement, Roche will pay $700 million…